The MAPK signal-integrating kinases Mnk1 and Mnk2 are closely related but show marked differences in their basal activities and regulation. Both possess, within their C termini, motifs for binding to MAPKs, although these differ between Mnk1 and Mnk2. Mnk2 shows much higher activity in unstimulated cells than Mnk1, whose activity is greatly increased, e.g. by stimulation of the MEK/ ERK pathway. Such increases are sensitive to blockade of that pathway, whereas the activation state of Mnk2 is relatively insensitive to inhibition of upstream signaling. Here we have studied the roles of features in their catalytic domains and C termini in determining their regulatory properties and basal activities. Mnk2 can bind to phosphorylated, active ERK, whereas Mnk1 cannot. Such binding apparently protects ERK against dephosphorylation and inactivation. The high basal activity of Mnk2 and its binding to (phospho)ERK requires features both of the catalytic domain and of the C terminus. For example, within the catalytic region an aspartate in Mnk2 plays a key role. Mutation to alanine inactivates Mnk2. In the C terminus, features within the MAPK-binding motif and to either side of it, including potential phosphorylation sites, affect MAPK binding and activity. The association of Mnks with the scaffold protein eukaryotic initiation factor 4G is negatively modulated by Mnk activity. These data indicate that multiple features determine the activities of the Mnks and thus impact on their ability to phosphorylate physiological substrates such as eukaryotic initiation factor 4E.
for capped mRNA (7, 8) , although the role of eIF4E phosphorylation in translation remains unclear (9) . Mice in which the Mnk genes have been inactivated were recently described. The animals were viable and showed no overt phenotype (10) .
There are two Mnk genes in mouse and human, termed Mnk1 and Mnk2 (11) . In human, each gives rise to at least two distinct proteins, with different C termini, as a consequence of alternative splicing (4, 6, 12) . The longer forms of human Mnk1 and Mnk2, referred to as Mnk1a and Mnk2a, possess a MAPK-binding motif that is absent from the shorter isoforms Mnk1b and Mnk2b. The longer forms correspond to those first discovered by Fukunaga and Hunter and by Waskiewicz et al. (1, 2) . The corresponding murine proteins are simply termed Mnk1 and Mnk2, as no short forms have yet been identified in mice.
Mnk1 has a low basal activity but in mammalian cells is highly activated following cellular stimulation. Its MAPK-binding motif can bind either ERK or p38 MAPK. Mnk1a is activated by treatments that stimulate either pathway and its activation is eliminated by compounds that block ERK or p38 MAPK signaling (3) (4) (5) . In contrast, Mnk2 shows a very high basal activity in serum-starved cells that does not significantly increase upon activation of ERK by phorbol esters. Furthermore, the compounds PD98059 and SB203580 (which inhibit MEK and p38 MAPK, respectively) had little effect on Mnk2 activity (3, 4) .
Mnk1 possesses a MAPK-binding domain that allows it to bind ERK and p38 MAPK, but not JNK (2) . Mnk2a is reported to bind preferentially to ERK, rather than to p38 MAPK, and not to JNK (2) . In vitro Mnk2a is much more effectively activated by ERK than p38 MAPK (2, 3, 13) . Thus, Mnk2/2a has high basal activity, whereas Mnk1/1a has low basal activity that is stimulated by the ERK and p38 MAPK pathways. MAPKs such as ERK possess a common binding site through which they interact with their activators (e.g. MEK) and substrates (such as RSK and the Mnks) (14) . It is also through this region that they bind the dualspecificity MAPK phosphatases (MKPs) that dephosphorylate and inactivate MAPKs (14) .
The MAPKs phosphorylate Thr-Pro sites in the T-loop of Mnk1. Phosphorylation of residues within the T-loop (between subdomains VII and VIII) of protein kinases generally leads to their activation (15) . Accordingly, the mutation of these residues to Ala abolishes the activation of the Mnks by ERK or p38 MAPK (2, 3) . However, there are potentially important differences in the amino acid sequences within the T-loop regions of Mnk1 and Mnk2.
To phosphorylate eIF4E the Mnks must bind eIF4G (16, 17) . Recently it has been reported that phosphorylation of Mnk1 by caspase-activated Pak2/␥-PAK inhibits the phosphorylation of Mnk1 and its interaction with eIF4G (18) , but the basis of this effect was not clear. Also, previous data showed that the Mnks dissociate from eIF4G after TPA stimulation (3) . Therefore, in vivo, the mechanisms that regulate the interaction with the scaffolding protein eIF4G may regulate the ability of the Mnks to phosphorylate their best-known substrate, eIF4E.
It is clearly important to understand what features explain the marked differences in activity between Mnk1 and Mnk2, and what underlies the modulation of their association with eIF4G. Here, we have studied features in the C termini and catalytic domains of Mnk1 and Mnk2 that may explain differences in their activity and regulation, and affect their binding to eIF4G.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfections-Human embryonic kidney 293 cells were grown in 10-cm plates in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen). Transient transfections were carried out by calcium phosphate precipitation of the DNA in N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES)-buffered saline, pH 6.96, with cells at a density of ϳ6 ϫ 10 5 to 8 ϫ 10 5 per 6-cm plate or 1.5 ϫ 10 6 to 2 ϫ 10 6 per 10-cm plate. PD98059 and SB203580 (both from Calbiochem) were used at final concentrations of 50 and 10 M, respectively.
Cell Harvesting-After treatments, cells were washed once with phosphate-buffered saline and harvested in 400 l of harvesting buffer (20 mM HEPES⅐KOH, pH 7.5, 50 mM ␤-glycerophosphate, 0.2 mM EDTA, 10% glycerol, 1% Triton X-100, 1 mM dithiothreitol, 0.5 mM sodium orthovanadate, 1 mM phenylmethanesulfonyl fluoride, 1 mM benzamidine, and 1 g each of leupeptin, antipain, and pepstatin). Cell debris and nuclei were spun down for 1 min at 12,000 ϫ g, and the supernatant was transferred to a new tube.
Immunoprecipitation-For anti-Myc immunoprecipitations, 2 l of antibody was added to cell extracts, and the mixture was incubated for 1 h at 4°C. Subsequently, protein G beads (20 l of packed beads per immunoprecipitation) in wash buffer (harvesting buffer without Triton X-100) were added and allowed to bind the antibody for an additional hour at 4°C. The beads were then washed three times with 500 l of wash buffer and finally resuspended in SDS-PAGE loading buffer. For detection of Mnk-bound eIF4G, cells were harvested in 10 mM HEPES⅐KOH (pH 7.4), 50 mM sodium fluoride, 2 mM EDTA, 1% Triton X-100, 14 mM ␤-mercaptoethanol, 0.5 mM sodium orthovanadate, and proteinase inhibitors as above. The incubations with the antibody and protein G and the subsequent wash steps were carried out with the same buffer.
Kinase Assays-Five-microliter aliquots of the beads with bound Myc fusion proteins, obtained as described above, were incubated in a total volume of 30 l in 20 mM HEPES-KOH (pH 7.5), 50 mM KCl, 2 mM MgCl 2 , 200 M ATP, 1 Ci of [␥-32 P]ATP, and 200 ng of recombinant eIF4E for 1 h at 30°C. The reaction was stopped by adding SDS-PAGE sample buffer and heating the sample for 5 min at 95°C. Samples were analyzed by SDS-PAGE and autoradiography.
Isoelectric Focusing-Endogenous eIF4E was purified by m 7 GTPSepharose chromatography, separated into phosphorylated and dephosphorylated species by isoelectric focusing, and detected by Western blotting as described previously (12, 21) .
Plasmids-pCS3MT Mnk1 has been described previously (22 401 3 Ala mutations were created using the QuikChange® kit from Stratagene. The Mnk1-C2 and Mnk2-C1 mutations were created by introducing a SacI restriction site at position Glu364 in pCS3MT Mnk1 and pCS3MT Mnk2 using the QuikChange® kit from Stratagene.
Then double digestion with SacI-HindIII was performed, and the sequences corresponding to the C terminus were swapped between both plasmids. DNA sequencing was performed by the Sequencing Service (School of Life Sciences, University of Dundee, Scotland (available at www.dnaseq.co.uk)) using a DYEnamic ET terminator chemistry (Amersham Biosciences) on Applied Biosystems automated DNA sequencers.
Antibodies-Total protein and phosphospecific antibodies for Mnk, ERK1/2, and p38 MAPK were obtained from Cell Signaling Technology, and the anti-Myc monoclonal antibody (9E10) was from Sigma. A monoclonal antibody was raised against recombinant human eIF4E (in collaboration with Dr. Borek Vojtesek, Academy of Sciences of the Czech Republic, Brno, Czech Republic), and the tissue culture supernatant was used for Western blotting following isoelectric focusing. Dr. Simon Morley (University of Sussex, Brighton, United Kingdom) kindly provided the eIF4G antibody.
In Vitro Labeling and Peptide Mapping-These procedures were performed as described previously (12) .
RESULTS

The C Termini of Mnk1 and Mnk2 Partially Explain the Differences in
Their Activity-The mouse proteins Mnk1 and Mnk2, which correspond to the human Mnk1a and Mnk2a, were used in this study. Previous work (3) using the mouse Mnks showed that, in HEK 293 cells, Mnk2 exhibit higher basal activity than Mnk1. Unlike Mnk2, Mnk1 activity is greatly enhanced by treating cells with agents that activate upstream signaling pathways ERK and p38 MAPK (5) .
A major objective of this study was to identify the features of Mnk2 that explain its higher basal activity compared with Mnk1 and, in particular, of the high basal activity of the former enzyme (which can be seen in Fig. 1C, top section) . Although Mnk1 and Mnk2 possess similar catalytic domains, there are some differences between them, e.g. in the amino acid sequences around the T-loop. The main differences between Mnk1 and Mnk2 lie in their C termini (Fig. 1A) , which contain distinct MAPK-binding motifs and also differ in several other respects. Indeed, apart from the MAPK-binding motif, the only point of similarity between these regions of mouse Mnk1 and Mnk2 is the Leu-Ser-ProPro-Ser sequence that lies N-terminal to the former motif (Fig. 1A) . The MAPK binding site in human Mnk1a reportedly gives it a better ability to bind p38 MAPK in comparison to Mnk2a (2) .
To study the roles of the C termini in determining the properties of Mnk1 and Mnk2, chimeric proteins were made in which the C-terminal region was swapped between both proteins (schematic representation in Fig. 1B) . The resulting chimera Mnk1-C2 consists of the C-terminal region of Mnk2 linked to the N terminus and catalytic domain of Mnk1, and vice versa for Mnk2-C1. HEK 293 cells were transfected with plasmids encoding Mnk1, Mnk2 or the chimeric proteins, Mnk1-C2 and Mnk2-C1. 24 h after transfection, cells were serum-starved for 14 h. In experiments where (P)ERK binding was analyzed, cells were pre-treated with TPA for 30 min (Fig. 1C) . Otherwise, cells were left untreated. Association with the upstream kinases ERK and p38 was analyzed by immunoprecipitating the Mnks with anti-myc followed by SDS-PAGE of the immunoprecipitates and Western blotting using anti-MAPK antibodies (Fig. 1C) . Mnk activity was assayed in vitro using recombinant eIF4E as substrate as described under "Experimental Procedures."
As expected, Mnk2 showed markedly higher basal activity than Mnk1 (Fig. 1C) . Strikingly, the variant containing the N terminus and catalytic domain of Mnk2 with the C terminus of Mnk1 (Mnk2-C1) showed a much lower activity than Mnk2, its activity being only slightly higher than that of Mnk1. This suggested that the C terminus of Mnk2 plays a FIGURE 1. The C termini of Mnk1 and Mnk2 explain some but not all differences in their activity. A, alignment of the sequences of mouse Mnk1 and Mnk2 using the Multalin software. The box indicates the region swapped in Mnk1-C2 and Mnk2-C1. B, schematic representation of the chimeric mutants obtained by exchanging the C termini of Mnk1 and Mnk2. C, pCS3MT constructs encoding for the Mnks were transfected into HEK 293 cells. After 24 h, the cells were serum-starved for 16 h and then treated with TPA for 30 min when the interaction with (P)ERK was studied, or left untreated when looking at the ERK interaction. The cells were then harvested, and the proteins were immunoprecipitated with anti-myc antibodies. Western blotting with anti-myc was used to check the expression levels of these proteins. The binding to the upstream kinases ERK, (P)ERK, and p38 was analyzed using the corresponding antibodies described under "Experimental Procedures." To study kinase activity, the myc-immunoprecipitated kinases from TPA-stimulated cells were incubated with recombinant eIF4E and [␥-32 P]ATP, and phosphorylation of eIF4E was visualized by SDS-PAGE and autoradiography. D, Mnk2 still binds (P)ERK after 16 h of serum starvation. pCS3MT constructs encoding for the Mnks were transfected into HEK 293 cells. After 24 h, the cells were serum starved for 16 h. The cells were then harvested, and the proteins were immunoprecipitated with anti-myc antibodies. Western blotting with anti-myc was used to check the expression levels of these proteins. The binding to (P)ERK was analyzed by Western blot using anti-(P)ERK as described under "Experimental Procedures." E, pCS3MT constructs encoding fusion proteins of Mnk1 or Mnk2 were transfected and expressed in HEK 293 cells. After 24 h, cells were serum-starved for 16 h and then treated with TPA for 30 min. Proteins were immunoprecipitated with an antibody against the myc tag, and kinase assays using recombinant eIF4E were performed as described under "Experimental Procedures." Phosphorylation of eIF4E was analyzed by SDS-PAGE, followed by autoradiography.
key role in the high basal activity of this enzyme. However, the converse Mnk1-C2 chimera showed an activity very similar to that of Mnk1, indicating that the C terminus of Mnk2 is insufficient by itself to confer the high activity that is characteristic of Mnk2. This therefore suggests that one or more features outside the C-terminal region are also important. This idea is studied further in subsequent experiments.
It was previously shown by Waskiewicz et al. (2) that the phosphorylation of ERK reduces its ability to bind to Mnk1. In contrast, this study reveals that a marked feature of Mnk2 is its ability to bind phosphorylated ERK (Fig. 1C) , which persists even after prolonged serum starvation of the cells (Fig. 1D) . Indeed, although Mnk1, Mnk1-C2, Mnk2-C1, and Mnk2 all bound to ERK, only Mnk2 and, to a lesser extent, Mnk1-C2 bound to (P)ERK (Fig. 1C) . These data imply that features within the C terminus of Mnk2 are important for (P)ERK binding. Interestingly, Mnk2 does co-immunoprecipitate with p38 MAPK, although previous reports had suggested that it binds primarily to ERK (2) . However, the amount of p38 MAPK present in the Mnk2 immunoprecipitate was consistently lower than the amount associated with Mnk1. Mnk1-C2 showed lower p38 binding than Mnk1, and conversely, Mnk2-C1 bound better to p38 than Mnk2. This likely reflects the differences between their MAPK-binding motifs (13) . Effects on ERK binding were generally the converse of those for p38, presumably because p38 and ERK compete for binding to this motif. Thus the level of association with p38 MAPK correlates entirely with the presence or absence of the C-terminal region of Mnk1. Mnk2 or the chimeric protein that contains the C terminus of Mnk2 (Mnk1-C2) showed better ERK binding than Mnk1 or Mnk2-C1 (Fig. 1C) .
Previous studies did not compare the relative maximal activities of Mnk1 and Mnk2a under conditions where cells had been stimulated to activate Mnk1. Nor did the earlier studies examine their K m values for the substrate, eIF4E. To study their kinetic parameters, HEK 293 cells were transfected with vectors encoding myc-tagged Mnk1 and Mnk2 (pCS3MT Mnk1 and pCS3MT Mnk2). 24 h after transfection, cells were serum-starved for 16 h and then treated with TPA for 30 min. The proteins were immunoprecipitated using anti-myc and their activities assayed in vitro against recombinant eIF4E, across a range of substrate concentrations.
Even after stimulation of cells with TPA, Mnk2 was more active than Mnk1 at all substrate concentrations tested (Fig. 1E) . Analysis of the data obtained across a range of concentrations of eIF4E revealed that Mnk2 has a higher K m (5.6 nM) than Mnk1 (3.0 nM) for eIF4E, and that the relative V max of Mnk2 (100 arbitrary units) is seven times higher than that of Mnk1 (14.24 arbitrary units).
Binding to (P)ERK May Explain the Lack of Inhibition of Mnk2 by PD98059
-ERK has a conserved common docking site for its inactivators (the MKPs) and substrates such as the Mnks (2, 18) . One would expect that the stable binding of (P)ERK to Mnk2 could protect it from dephosphorylation, by preventing it from binding to MKPs. To test this idea, HEK 293 cells were transfected with vectors encoding myc-tagged Mnk1 or Mnk2 or with the empty vector (negative control). After 24 h, cells were starved of serum for 16 h, and then either treated with TPA for 30 min (to activate ERK) or treated with TPA followed by the MEK inhibitor PD98059 for 1 h (to elicit inactivation of ERK). Cell lysates were then analyzed for the levels of (P)ERK ( Fig. 2A) . As anticipated, TPA activated ERK, as seen by the increased signal with the phosphospecific anti-ERK antibody. Treatment with PD98059 reversed this effect in cells transfected with empty vector or Mnk1. However, in cells expressing Mnk2, the levels of (P)ERK remained markedly higher than in control cells or in those expressing Mnk1. The simplest interpretation of this finding is the one depicted in Fig. 2C , where the overexpressed Mnk2 binds a portion of the (P)ERK sufficiently stably to protect it from dephosphorylation by MKPs, even when MEK activation is blocked. In cells overexpressing Mnk1, (P)ERK is not protected against dephosphorylation, because it does not interact with Mnk1. Consequently (P)ERK is accessible to phosphatases and is dephosphorylated and inactivated. This may explain the persistent high activity of overexpressed Mnk2 after serum starvation or treatment of cells with the signaling inhibitors PD98059 and SB203580, because Mnk2 both binds its activated upstream kinase, (P)ERK, and also protects it from dephosphorylation. As described below (see Fig. 5 ), we conducted further experiments to test this idea. Even after treatment of cells with PD98059 to block MEK and activation of ERK, some (P)ERK remained associated with Mnk2 (Fig. 2B) .
It should be noted that we are not arguing that the role of Mnk2 is to protect the main cellular population of ERK from MKP-mediated dephosphorylation, but rather that the interaction with Mnk2 serves to keep the Mnk2-associated pool of ERK in its active, phosphorylated, state.
An Aspartate Adjacent to the T-loop Plays a Key Role in Determining the Activity of Mnk2-The data for the chimeric Mnk proteins revealed that the differences between the C termini of Mnk1 and Mnk2 cannot fully explain their differing activities and suggested that features in the catalytic domain are also an important determinant here. Phosphorylation of residues within the T-loop of the catalytic domain (within subdomain VIII) of many protein kinases is crucial for their activation. This is also true for the Mnks, where MAPKs phosphorylate two threonyl residues in that region (Thr 197/202 (2, 3) ). Converting these residues to non-phosphorylatable alanyl residues yields mutants that cannot be activated (1, 3 by an aspartate in Mnk2, Asp 191 (Fig. 3A) . Because negatively charged aspartate or glutamate residues may mimic phosphorylated serine or threonine, it was possible that Asp 191 might play a role in the higher activity of Mnk2. For example, the presence of a negatively charged residue here could be important for the activity/activation of the kinase. According to this idea, Mnk2 would then be basally active, whereas Mnk1 might require phosphorylation at this position to be "fully" active.
To test this, selected mutations in the catalytic domain of Mnk1 and Mnk2 were generated. The first one was Asp 191 to Ala in Mnk2. HEK 293 cells were transfected with Mnk1, Mnk2, Mnk2 D191A, or the empty vector (negative control). The resulting cell lysates were subjected to affinity chromatography on m 7 GTP-Sepharose (to purify eIF4E) and the levels of eIF4E phosphorylation were analyzed by isoelectric focusing/immunoblotting using anti-eIF4E, as a means of assessing the in vivo activity of the Mnk proteins. As anticipated, ectopic expression of Mnk1 increased eIF4E phosphorylation under these conditions (Fig. 3B) . Overexpression of wild-type Mnk2 enhanced the phosphorylation of the endogenous eIF4E to a greater extent than Mnk1. In contrast, Mnk2 D191A was inactive in vivo. To study this further, the activities of WT Mnk2 or the D191A mutant were measured after immunoprecipitation from lysates of cells that had in some cases been treated with TPA. As shown in Fig. 3C , the D191A mutant displayed no activity either under basal conditions or after TPA stimulation. Thus, Asp 191 plays a crucial role in the basal or stimulated activity of Mnk2.
Because this aspartate residue is crucial for the activity of the catalytic domain of wild-type Mnk2, one might expect that an Mnk1 mutant carrying an aspartate in this position (Mnk1 S191D) would display higher activity. To study this, two new mutants of Mnk1 were obtained: (i) Mnk1 S191D, where Ser 191 was replaced by an Asp, and (ii) Mnk1 S191D-C2, a mutant where Ser 191 was replaced by an Asp and C terminus is substituted by that of Mnk2 (a variant of the chimera shown earlier to have slightly enhanced activity as compared with wild-type Mnk1, Fig. 1C ).
To test whether Ser 191 in Mnk1 was a site of phosphorylation, we first expressed WT Mnk1 or Mnk1 S191D in HEK 293 cells, which were then metabolically labeled using [ 32 P]orthophosphate. The radiolabeled Mnk proteins were immunoprecipitated and purified by SDS-PAGE, and the corresponding bands were excised and digested with trypsin followed by Asp-N. The resulting phosphopeptides were displayed by standard two-dimensional mapping (Fig. 4A) . Comparison of the maps for WT Mnk1 and Mnk1 S191D reveals that one major phosphopeptide is missing from the latter, strongly suggesting that Ser 191 is a site of phosphorylation. Because this residue is not in a consensus for MAPK phosphorylation (it is not followed by a proline), we wondered whether this was a site for autophosphorylation. To test this, we required a kinase-dead version of Mnk1. Previously, the T-loop threonines have been mutated to alanine to try to create an inactive version of the enzyme. However, although they do have decreased activity relative to the wild-type protein (see, e.g. Refs. 2 and 4), such mutants do still have display residual activity. 3 To try to generate truly inactive variants, we substituted Asp 158 in the His-Arg-Asp motifs of Mnk1 and Mnk2 (in subdomain VIB) for alanine. As shown in Fig. 4B , the resulting Asp/Ala mutants were devoid of activity. This is as expected, because the aspartate plays a critical role in the phosphotransferase reaction.
When the peptide-mapping analysis was performed for this mutant, the peptide absent in the S191D mutant was still observed (Fig. 4A) , strongly implying that this residue is not phosphorylated autocatalytically, but rather by another protein kinase, although as noted this is unlikely to be a MAPK. However, use of specific signaling inhibitors would be required to confirm this.
We also tested the activities of the new Mnk1 mutants and their abilities to bind (P)ERK. As shown in Fig. 4C , Mnk1 S191D displayed higher activity than Mnk1, but this was still lower than for Mnk2. Moreover, Mnk1 S191D-C2 showed similar activity in vitro to the wild-type Mnk2, which was thus higher than the activity of the Mnk1-C2 chimera. This strongly suggests that the high activity of Mnk2 may be explained by the properties conferred by its C terminus and by a single amino acid residue in the T-loop region. A second notable feature of Mnk1 S190D-C2 was its ability to bind phosphorylated ERK after TPA treatment (Fig. 4D) . The T-loop substitution and C-terminal swap together suffice to allow a degree of stable binding to (P)ERK.
Given that Ser 191 does appear to be a site for phosphorylation in Mnk1, we also made a S191A mutant. Although the S191D mutation increased the activity of Mnk1, in contrast to the situation for Mnk2, the 3 M. Buxadé , unpublished data. by a non-phosphorylatable residue does not destroy activity, it appears that phosphorylation of Ser 191 in Mnk1 is not essential for its activity. To study this further, we also made a mutant containing an asparagine at this position: this residue is similar in overall geometry to aspartate but lacks a negative charge. As shown in Fig. 4F , its activity was similar to that of wild-type Mnk1. Indeed, as also seen from Fig. 4F , the basal and TPA-stimulated activities of the S191A, S191N, and WT Mnk1 proteins were similar, with only the S191D mutant showing enhanced activity (under both unstimulated and TPA-activated conditions). The effect of placing an Asp in this position is apparently not due to mimicry of phosphoserine, even though the serine here in Wt Mnk1 does appear to be phosphorylated. The serine may play other roles. Overall, the data in Fig. 4 show that the differing activities of Mnk1 and Mnk2 are determined not only by differences in their C termini but also by a single residue difference within their catalytic domains.
Features Near the MAPK Binding Site Determine the Ability of Mnks to Bind to ERK-
The MAPK binding sites in Mnk1 and Mnk2 are situated near their C termini, but Mnk1 and Mnk2 contain slightly different versions of this motif (Fig. 5A) . In particular, Mnk1 contains the sequence LARRR, whereas in Mnk2 the sequence is LAQRR. Previous published data show that mutating the Leu residue to an Ala in Mnk2 greatly decreased ERK binding and, to a lesser extent, the phosphorylation of the T-loop (12) . This mutation also decreased Mnk2 activity both in vivo and in vitro (4) . The corresponding mutation in Mnk1 (to create Mnk1 L391A) also eliminated ERK and p38 MAPK binding (Fig. 5B) . To study directly the consequences of the differences between the MAPK binding sequences of Mnk1 and Mnk2, we made an Mnk1 mutant containing the MAPK-binding motif of Mnk2 (Mnk1 LAQRR) and vice versa for Mnk2 (Mnk2 LARRR). As expected, Mnk1 LAQRR showed increased ERK binding compared with wild-type Mnk1 and, to a small extent, decreased p38 MAPK binding (Fig. 5B) . This is consistent with the idea that the LAQRR motif is more favorable for ERK binding. Conversely, Mnk2 LARRR exhibited substantially increased binding to p38 MAPK relative to wild-type Mnk2. The most striking finding was that Mnk2 LARRR was unable to bind (P)ERK, differing in this regard from WT Mnk2 (Fig. 5B) . Although this result indicates that the Arg or Gln residues at this position are involved in determining ability to bind (P)ERK, this cannot be a dominant feature, because Mnk1 LAQRR did not bind to phosphorylated ERK (Fig. 5B) . Therefore, other features of Mnk2 must function with the Gln at this position to confer binding to (P)ERK.
When phosphorylation in the activation T-loop was studied, it was clear that the LAQRR mutant of Mnk1 showed rather similar levels of phosphorylation to wild-type Mnk1 (Fig. 5C ). The converse mutation in Mnk2 (LARRR) caused a pronounced decrease in T-loop phosphorylation, likely due to the inability of this variant to bind to (P)ERK (Fig. 5, B and C). In both Mnk1 and Mnk2, the L391A mutant showed almost complete loss of T-loop phosphorylation, consistent with the inability of these mutated proteins to bind the upstream kinases (Fig. 5C) .
The finding that the LARRR mutant of Mnk2 did not bind to (P)ERK (Fig. 5B ) allowed us to test whether this interaction normally accounts for the high activity of Mnk2 and its resistance to blockade of the MEK/ ERK and p38 MAPK pathways. In addition, the observation (Fig. 4D ) that Mnk1 S191D C2 binds (P)ERK better than Mnk1 itself prompted to ask whether this variant showed altered sensitivity to stimulation or inhibition of upstream signaling. Consistent with the data in Fig. 4D , Mnk1 S191D C2 showed higher basal activity than Mnk1, although its TPA-stimulated activity was apparently similar (Fig. 5D ). This variant also showed some residual activity after treatment of cells with PD98059 and SB203580, whereas Mnk1 itself was completely inhibited by the combination of these two signaling inhibitors (Fig. 5, D and E) . Quite strikingly, whereas the activity of Mnk2 was only partially decreased by the signaling inhibitors, Mnk2 LARRR (which cannot bind (P)ERK) was completely inhibited under this condition (Fig. 5D) . This difference was also seen clearly when the effect of these compounds was studied over a time course (Fig. 5E ). In this case, the activity of Mnk2 declined more slowly than that of Mnk2(LARRR). The fact that this single point mutation in the MAPK-binding motif of Mnk2 both abolished (P)ERK binding and rendered Mnk2 sensitive to inhibition of upstream signaling strongly suggests that the normal resistance of Mnk2 to such inhibition is a consequence of its ability to bind (P)ERK. As described above, the binding of Mnk2 to (P)ERK both serves to recruit active ERK to phosphorylate Mnk2 and protect (P)ERK from dephosphorylation and inactivation. It is also very clear from the data in Fig. 5E that, although the activity of Mnk1 drops quickly and sharply after addition of the signaling Kinase assays were performed as described under "Experimental Procedures." C, lysates from HEK 293 cells transfected with the plasmids coding for Mnk1 and Mnk1 S191D-C2 were subjected to immunoprecipitation using an anti-myc antibody. The binding to the upstream kinase (P)ERK was analyzed using the phosphospecific antibody against that protein. D, kinase assays were performed as described under "Experimental Procedures," from proteins pulled down from lysates after TPA treatment using myc antibody. The lower part shows the phosphorylation of eIF4E visualized by SDS-PAGE and autoradiography, whereas the upper part shows the section of the Coomassie blue-stained gel corresponding to the Mnks as loading control. E, HEK 293 cells were transfected with the indicated Mnk constructs. After 24 h, cells were serum-starved for 16 h and then treated with TPA for 30 min where indicated. Kinase assays were performed as described under "Experimental Procedures." Phosphorylation of eIF4E was visualized by SDS-PAGE and autoradiography. F, HEK 293 cells were transfected with the indicated Mnk constructs. After 24 h, cells were serum-starved for 16 h and then treated with TPA for 30 min where indicated. Kinase assays were performed as described under "Experimental Procedures," from proteins pulled down using anti-myc from lysates of cells that had been treated with TPA. Phosphorylation of elF4E was visualized by SDS-PAGE and autoradiography.
inhibitors, the activity of Mnk1 S191D C2, which can bind (P)ERK (Fig.  4D) , is quite resistant to upstream signaling blockade.
Role of Residues N-terminal to the MAPK-binding Motif-
The association between ERK and its substrates (e.g. RSKs) can be regulated by phosphorylation at residues near the ERK-binding domain (21) . Our group has previously shown that two serine residues in mouse Mnk2, Ser 384 and Ser 387 , which are N-terminal to the MAPK-binding domain, are phosphorylated in vivo after TPA stimulation (3). These lie in the Leu-Ser-Pro-Pro-Ser feature, which is common to mouse Mnk1 and Mnk2 (Fig. 6A) . Human Mnk1 also contains a Ser residue at position 384, but Ser 387 is replaced by Cys. To address whether Ser 384 is also phosphorylated in Mnk1 in vivo, Mnk1 or Mnk1 S384A mutant were immunoprecipitated from metabolically [ 32 P]orthophosphate-labeled HEK 293 cells. The radiolabeled protein was digested with trypsin followed by Asp-N, and the resulting peptides were analyzed by two-dimensional mapping as described under "Experimental Procedures" (Fig.  6B ). In agreement with earlier studies on Mnk1 (22) , a number of labeled peptides were seen, corresponding to phosphorylation sites within Mnk1. On the maps, one minor peptide was absent from the maps derived from the Mnk1 S384A variant, suggesting that in Mnk1 this residue is phosphorylated as it is in Mnk2 (3), but only to a low level. Because Ser 384 and Ser 387 would be contained in the same tryptic peptide, and because no additional peptide appeared after mutation of Ser 384 to alanine, the data imply that Ser 387 is not phosphorylated in mouse Mnk1. This is not surprising because, as already noted, this residue is not conserved in the human ortholog.
To study whether Ser 384 is involved in regulating the binding to upstream MAPKs, different mutations at this site were generated to introduce negatively charged (Glu, or Asp (not shown), which could act as phosphomimetics) or non-phosphorylatable (Ala or Gln) residues. Similarly, Ser 387 was also replaced by other residues. In Mnk1, the replacement of Ser 384 by an alanine increased its binding to ERK and (P)ERK severalfold (Fig. 6C) . However, in Mnk2, the replacement of Ser 384 by alanine had no effect on binding to ERK or (P)ERK (Fig. 6D ). This could suggest that phosphorylation at Ser 384 negatively regulates ERK association in Mnk1 but not in Mnk2, although Ser 384 is phosphorylated in Mnk2 (12) . Other features in the C terminus of Mnk2 may stabilize its binding to ERK independently of Ser 384 phosphorylation. Unexpectedly, the replacement of Ser 384 by glutamate, which can sometimes mimic phosphorylation, actually caused increased binding to ERK and (P)ERK in Mnk1 (Fig. 6C) . To assess whether this increase was due to a structural change or to the negative charge introduced, Ser 384 was also mutated to Gln, an un-charged residue. Mnk1 S384Q showed similar binding to ERK and (P)ERK as the glutamate mutants (Fig. 6, C and D) . This indicates that the effect of the glutamate residues is not due to their negative charge and presumably not therefore to mimicry of phospho-serine. For all the mutants at position 384, ERK and (P)ERK binding changed in parallel, so that this position modulates ERK binding rather than having a selective effect on (P)ERK association.
As mentioned above, Ser 387 in Mnk2 is also phosphorylated in vivo (3) (but apparently not in Mnk1, see above). To study the possible role of this phosphorylation in ERK association, further mutants were created in Mnk2. Although Mnk2 S387E (Fig. 6D) bound both ERK and (P)ERK (like WT Mnk2), the S387A mutant bound ERK but not (P)ERK. Thus, in Mnk2, Ser 387 or its phosphorylation may be crucial for its binding to (P)ERK. However, no further means is available by which we can assess this.
Features That Lie C-terminal to the MAPK-binding Motif Also Affect Interactions with ERK or (P)ERK-Ser
749 in avian RSK has been reported to negatively control ERK binding (21) . In Mnk2, this corresponds to Ser 401 (Fig. 6A) , which is not in a consensus for phosphorylation by MAPK (it is not followed by a proline). If, like Ser 749 in RSK1, Ser 401 were phosphorylated, one might expect Mnk2 to be unable to bind ERK/ (P)ERK. Previous work in this laboratory provided evidence that Ser 399 is phosphorylated in Mnk2 (3) but not that Ser 401 was phosphorylated. To study whether they play a role in regulating binding to ERK, mutations to a non-phosphorylatable amino acid (alanine, Mnk2 S399A and Mnk2 S401A) or to a negatively charged residue (potentially phosphomimetic, aspartate; Mnk2 S399D and Mnk2 S401D) were made. Although Mnk2 S399A or Mnk2 S399D showed similar ERK binding to wild-type Mnk2, the replacement of Ser 401 by aspartate dramatically decreased the binding to ERK (Fig. 7B) . However, Mnk2 S401A showed the same binding to ERK as wild-type Mnk2. Thus, a negatively charged residue at this position interferes with ERK binding. Although the corresponding residue in RSK1 is phosphorylated, Ser 401 in Mnk2 does not appear to be (3), and this may explain why Mnk2 can bind (P)ERK while the RSK protein cannot.
Looking for residues that might modulate MAPK binding in Mnk2, our attention was also drawn to the Leu between the two serines described above, i.e. Leu 400 (Fig. 7A) . Leucine residues are often involved in protein-protein interactions. This residue is also a hydrophobic one in RSKs 1-3, whereas it is an alanine in Mnk1 (the flanking serines are also replaced by other residues in Mnk1, so the comparison here is not straightforward). We therefore altered Leu 400 to an Ala and tested ERK binding. The resulting mutant, Mnk2 L400A, was unable to bind either ERK or p38 MAPK (Fig. 7B ). This result shows the importance of this hydrophobic residue in Mnk2 for binding to MAPKs. Hydrophobic residues in the corresponding positions in the ERK binding regions of MEK1 (ϩ4 after the 3 basic residues) (23) and MKP1 (ϩ5, as in Mnk2) (24) have been reported to be important for their interaction with their MAPK partners. All these data suggest that features that lie C-terminal to the main MAPK binding site play important roles in regulating the interactions between Mnk2 and ERK/p38 MAPK. To get a more complete picture of the possible reasons for the differences between Mnk1 and Mnk2 in terms of MAPK binding, we inspected the region C-terminal to the MAPK-binding motif for other features that might be important for the ERK binding. Immediately after the pair of arginines in the MAPK binding site, the sequence in Mnk2 is Gln-Arg-Ala (QRA, residues 396 -398). This is replaced by Ala-Leu-Ala (ALA) in Mnk1 (Fig. 6A) . This is true for Mnks from mouse and human. Replacement of Arg 397 in Mnk2
by Leu greatly decreased binding to ERK and dramatically decreased the interaction with (P)ERK (Fig. 7C) . This suggests that an Arg at this position is critical for ERK and (P)ERK binding. The converse mutation in Mnk1 (L397R) allowed a small increase in ERK binding, and Mnk1 L397R was also able to bind (P)ERK (Fig. 7D) . Thus, Arg 398 in Mnk2 appears to be crucial for binding to (P)ERK. However, other features may be involved, because Mnk1 L397R still showed less binding to (P)ERK than Mnk2. 
The Binding of Mnks to the Scaffolding Protein eIF4G Is Regulated by
Their Activities-To phosphorylate eIF4E efficiently, the Mnks must bind the translation factor eIF4G, which also binds eIF4E (4, 16, 17, 22) . Regulation of the Mnk-eIF4G interaction could consequently provide an additional way of modulating eIF4E phosphorylation in vivo. We therefore studied the binding to eIF4G of wild-type Mnk1 and Mnk2. Mnk1 consistently bound better to eIF4G than Mnk2 did (Fig. 8A) . In view of the facts that TPA promotes the dissociation of the Mnks from eIF4G (3) and that Mnk2 is much more active than Mnk1 under basal conditions, we wondered whether decreased eIF4G binding corresponded to higher Mnk kinase activity. To address this, we first wished to examine the binding of eIF4G to kinase-dead (KD) mutants of the Mnks.
As shown in Fig. 8B , kinase-dead Mnk1 and Mnk2 bound better to eIF4G than the wild-type proteins: taking into account the lower level of expression of Mnk2 KD, the level of eIF4G binding is similar to that for Mnk1 KD. This increased binding of the kinase-dead mutants could, in principle, arise because the mutation affects the structure of the enzyme as well as its activity. As an alternative approach, we therefore tested the effect of the Mnk inhibitor CGP57380 (19, 20) , which avoids any potential complications arising from introducing mutations. Treatment of cells with the Mnk inhibitor increased the binding of wild-type Mnk1 to eIF4G (Fig. 8A, right-hand part) . Therefore, the increase in binding was not due to a structural change caused by the mutation in the kinasedead mutants. All these data suggest that there is indeed an inverse relationship between Mnk activity and eIF4G binding.
DISCUSSION
Compared with other protein kinases that lie downstream of MAPKs, such as the RSKs, rather little is known about the interactions and regulation of the Mnks. The data presented here provide important new insights into features that account for the different activities and regulatory characteristics of Mnk1 and Mnk2, their differential binding to ERK and (P)ERK, and the modulation of their binding to eIF4G.
Mnk1 shows much lower basal activity than Mnk2, and the high basal activity of the latter enzyme is rather resistant to inhibition of the p38 MAPK and ERK pathways. Further, the present data show, even after stimulation of cells with TPA to activate Mnk1, much lower activity than Mnk2. Under non-stimulated conditions, the difference in activity is even greater. One aim of this study was to identify the features in Mnk2 that account for this high basal activity and for its resistance to inhibition of upstream signaling pathways.
Mnk1 and Mnk2 share a similar N-terminal region but show several differences in their C termini. These include distinct MAPK-binding motifs but also a number of other differences (2) . To study the roles of the C termini in determining the distinct properties of Mnk1 and Mnk2, we analyzed chimeric proteins, consisting of Mnk1 with the C terminus of Mnk2 and vice versa. Although replacing the C terminus of Mnk2 with that of Mnk1 yielded a chimera with much lower activity than Mnk2, the converse swap failed to generate a chimera with similar activity to Mnk2. This suggested that features of both the C terminus and the catalytic domain are important for the high activity of Mnk2. The T-loop regions of protein kinases play a key role in regulating their activity, and the T-loops of Mnk1/2 contain residues that are phosphorylated by the upstream activators, ERK and p38 MAPK. Our studies revealed that a feature in the T-loop of the catalytic domain of Mnk2, i.e. Asp 191 , is important for its higher activity. Mutation of Asp 191 to Ala in Mnk2 led to its inactivation. This residue corresponds to a serine in Mnk1 and mutation of Ser 191 in Mnk1 to Asp led to an increase in its activity. However, the activity of Mnk1 S191D was still lower than that of Mnk2, suggesting that other features are also involved. Indeed, the combination of replacing the T-loop Ser by Asp in the catalytic domain of Mnk1 and substituting its C-terminal region for that of Mnk2 yielded a protein that showed similar activity to Mnk2 itself. One note of caution in studying the effects of point mutants on protein function is that they may exert unknown effects on the structure of the protein. Nonetheless our data do indicate that the high basal activity of Mnk2 (as compared with Mnk1) appears to be explained by a single residue near the T-loop and features of its C terminus.
A striking feature of Mnk2 is its ability to bind to (P)ERK. The Mnk1 chimera/mutant consisting of the C terminus of Mnk2 and the Ser 191 Asp also bound (P)ERK, whereas individually the C-terminal exchanges or Ser 191 Asp mutation did not have this effect. It was then important to identify which features in Mnk2 allowed it to bind the upstream kinase (P)ERK. We first tested whether this ability was simply conferred by the core MAPK-binding motif itself, which is LARRR in Mnk1 and LAQRR in Mnk2. To study the importance of these domains in the binding to the upstream regulators, we exchanged these motifs between Mnk1 and Mnk2. The MAPK-binding motif in Mnk1 gives it better ability to bind p38 MAPK as compared with Mnk2. As expected, the motif LAQRR gave better binding to ERK and worse binding to p38.
Replacement of the glutamine by arginine in Mnk2 resulted in a loss of ability to bind (P)ERK suggesting that this residue is critical for this interaction: however, the presence of a glutamine here is not in itself sufficient, because the Mnk1(LAQRR) mutant does not bind (P)ERK. This implies that other features of Mnk2 are also important for (P)ERK binding here, and we set out to study this.
Inspection of the remainder of the C termini of mouse Mnk1 and Mnk2 revealed one feature that they share and other features that differ between them and may be important in their differential binding to (P)ERK. The shared feature is the Leu-Ser-Pro-Pro-Ser sequence that lies N-terminal to the MAPK-binding motif. It should be noted that the second Ser is replaced by Cys in human Mnk1. Our previous analysis had revealed that both serines are phosphorylated in mouse Mnk2 in vivo (Ser 384 Ͼ Ser 387 ) (3). These serines (Ser 384 and Ser 387 ) were mutated to non-phosphorylatable residues, to a negatively charged residue that may mimic phosphoserine (Glu) or to a positively charged residue (Lys). The findings derived from these experiments show that mutation of Ser 384 to Ala increased the binding of Mnk1 to ERK and (P)ERK, which could suggest that phosphorylation here may negatively regulate the binding of ERK to Mnk1. However, mutation to the potentially phosphomimetic residue Glu also increased ERK and (P)ERK binding. This residue does appear to be phosphorylated within cells, but the fact that the S384A and S384E mutants show similar ERK-binding characteristics makes it unclear whether phosphorylation here really is a negative determinant of ERK binding. Phosphorylation of Ser 384 is not due to autophosphorylation, and nor is it likely to be mediated by a MAPK, so that additional kinases may phosphorylate Mnk1 when overexpressed in HEK293 cells.
In Mnk2, mutation of Ser 384 to Ala, Gln, or Glu had no marked effect on ERK or (P)ERK binding. In contrast to the situation for Mnk1, its mutation to Lys abolished ERK and (P)ERK binding. Interestingly, mutation of Ser 387 to Ala in Mnk2 did not change the binding of Mnk2 to ERK but eliminated binding to (P)ERK. This could indicate a possible role for the phosphorylation of this residue in stabilizing the Mnk2/ (P)ERK interaction.
Interestingly, the MAPK docking domain (LAQRR) in RSK1-4 is identical to the one found in Mnk2, and an alignment of the C termini of these proteins revealed conserved residues near the MAPK binding site. The alignment also showed that the residue corresponding to Ser 384 in Mnk2 differs in the four RSK isoforms. Although RSK1 contains a basic residue in this position (Lys), the other three isoforms contain an acidic residue (Glu). A noteworthy difference between these isoforms is the fact that after mitogenic stimulation, RSK1, but not RSK2 or RSK3, dissociates from ERK (21) . The region containing the ERK docking site in the RSK family is highly conserved, with few differences between the isoforms. The differences between Mnk2 S384K and Mnk2 S384E in their binding to ERK may explain the different ERK-binding characteristics of these members of the RSK family. However, testing this lies beyond the scope of the present study.
There are no obvious completely common features C-terminal to the MAPK binding sites in Mnk1 and Mnk2. The differences here may therefore be important for the distinct abilities of Mnk1 and Mnk2 to bind (P)ERK. Arg 397 in Mnk2 seems to play a critical role in the ability of Mnk2 to bind (P)ERK.
The association of RSK1 with ERK is negatively regulated through phosphorylation of Ser 749 (21) . This serine corresponds to Ser 401 in mouse Mnk2. The neighboring serine at 399 is phosphorylated in Mnk2 in vivo (3) . We therefore studied the relevance of these residues for the binding of Mnk2 to ERK. Studies involving mutations of Ser 399 to Ala or Asp revealed that this residue does not play a role in modulating the binding of ERK to Mnk2. In contrast, mutation of Ser 401 to Asp decreased the association of Mnk2 to ERK or (P)ERK. Because this residue may correspond to an aspartate in mouse Mnk1 (Fig. 6A) , this feature might be important in negatively modulating the binding of Mnk1 to ERK.
In Mnk2, there is a leucine between Ser 399 and Ser 401 (Leu 400 ), which corresponds to a similar residue in the RSK family, and it plays a crucial role in the interaction of Mnk2 with ERK, because its replacement by an alanine inhibits ERK binding. The fact that the ERK phosphatases share their docking site with the ERK activators and substrates could explain why Mnk2 is insensitive to the MEK inhibitor PD98059. The stable binding of a fraction of the cellular (P)ERK to Mnk2 appears to render it inaccessible to the phosphatases (MAPK phosphatases, MKPs), impeding their binding and thus ERK inactivation. This feature also may explain the high basal activity of Mnk2 after serum starvation, because Mnk2 remains bound to residual (P)ERK under this condition, which can continue to phosphorylate Mnk2 and keep it in an activated state.
Finally, we studied the regulation of eIF4G/Mnk binding. The Mnks must bind the scaffolding protein eIF4G to phosphorylate eIF4E effi-ciently. Previously we showed that, after TPA stimulation, the binding of Mnks to eIF4G is decreased (3) . Moreover, recent work has shown that the interaction of eIF4G with the Mnks is regulated by phosphorylation of residues in Mnk near its eIF4G binding site by Pak2 (18) . The data presented here suggest that the extent of association with eIF4G is also dependent on the activation level of the Mnks. The kinase-dead versions of the Mnks bind better to eIF4G than the wild-type proteins. Similarly, treatment of cells with CGP57380 increased the binding of eIF4G to wild-type Mnks. The fact that Mnk2 is more active than Mnk1 might explain why Mnk1 normally binds better to eIF4G than Mnk2 does. Data for CGP57380 suggest that changes in this association are due to Mnk activity, rather than to an alteration in the structure of the Mnks when they become activated. The regulation of the Mnk/eIF4G binding may be of biological importance, because eIF4E can no longer be efficiently phosphorylated by the Mnks when they are not bound to eIF4G. The fact that activated Mnk binds less to eIF4G may serve to limit the extent or duration of the phosphorylation of eIF4E.
